Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2429567 | 0.78 | GPR119 (0.64) | GPR119ITGB3ITGA2BSLC6A4ITGAV | |
| SCHEMBL12103678 | 0.78 | ITGB3 (0.42) | GPR119ITGB3ITGA2BAVPR2AVPR1A | |
| Hydrochloric Acid SCHEMBL1295292 | 0.77 | ITGB3 (0.41) | GPR119ITGB3ITGA2BAVPR2AVPR1A | |
| SCHEMBL12205163 | 0.76 | GPR119 (0.49) | GPR119ITGB3ITGA2BSLC6A4ITGAV | |
| SCHEMBL1712981 | 0.75 | GPR119 (0.43) | GPR119 | |
| SCHEMBL1713133 | 0.73 | GPR119 (0.38) | GPR119 | |
| SCHEMBL12326026 | 0.73 | GPR119 (0.48) | GPR119ITGB3ITGA2BSLC6A4ITGAV | |
| SCHEMBL12325542 | 0.71 | GPR119 (0.54) | GPR119ITGB3ITGA2BSLC6A4ITGAV | |
| SCHEMBL12204971 | 0.71 | GPR119 (0.59) | GPR119ITGB3ITGA2BSLC6A4ITGAV | |
| SCHEMBL30670009 | 0.70 | AVPR2 (0.48) | ITGB3ITGA2BAVPR2AVPR1ATLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048631-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-2114932-A1 | PIPERIDINE GPCR AGONISTS | Prosidion Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008081206-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048631-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | GPR119 1/4885ITGB3 3540/4885ITGA2B 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.